On January 16, Guangdong Zhenzhong Raynovent Biotechnology Co., Ltd. ("Raynovent"), a holding subsidiary of Guangdong Zhenzhong Pharmaceutical Co., Ltd., signed a "License Agreement" with Qilu Pharmaceutical Co., Ltd. on January 16, 2026. Raynovent authorized Qilu Pharmaceutical to manufacture and commercially sell RAY1225 injection in the China region (including mainland China, Hong Kong, Macao, and Taiwan, collectively referred to as the "Licensed Territory"). Raynovent retains all rights, ownership, and interests of the licensed intellectual property. After the licensed product receives marketing authorization approval from the drug regulatory authorities, Raynovent will be the Marketing Authorization Holder (MAH). Meanwhile, Raynovent still holds all rights, ownership, and interests of RAY1225 injection outside of China, including but not limited to clinical development, manufacturing, new drug registration, sales, and marketing promotion.Under the terms of the licensing agreement, Raynovent will receive an upfront payment and milestone payments totaling RMB 1 billion, including an upfront payment of RMB 200 million, development and sales milestone payments up to a combined total of RMB 800 million, and is entitled to receive double-digit royalties on net sales of the licensed product following its commercial launch.The licensed product RAY1225 Injection, developed by raynovent, is an innovative peptide drug with global independent intellectual property rights. It exhibits dual agonist activity on GLP-1 and GIP receptors and, due to its excellent pharmacokinetic properties, has the potential to be an ultra-long-acting drug administered once every two weeks.
Currently, the Phase III clinical trial (REBUILDING-2 study) evaluating the safety and efficacy of RAY1225 injection for the treatment of obese/overweight patients in China, the Phase III clinical trial (SHINING-3) assessing the safety and efficacy of RAY1225 injection in combination with oral hypoglycemic drugs for type 2 diabetes patients compared with semaglutide injection, and the placebo-controlled Phase III clinical trial (SHINING-2) examining the safety and efficacy of RAY1225 injection as monotherapy for type 2 diabetes patients have all successfully completed participant enrollment. Raynovent will continue to uphold a rigorous approach, advancing the Phase III clinical trials of RAY1225 injection with high quality, efficiency, and scientific standards.Qilu Pharmaceutical Co., Ltd., headquartered in Jinan, Shandong Province, is a large comprehensive modern pharmaceutical enterprise in China, specializing in the research, production, and sales of formulations and active pharmaceutical ingredients for the treatment of cancer, cardiovascular and cerebrovascular diseases, anti-infectives, psychiatric and neurological disorders, and ophthalmic conditions. Qilu Pharmaceutical boasts a scientific and complete product structure, with over 300 products on the market, covering a wide range of therapeutic areas and featuring a well-rounded product portfolio. Relying on its solid product quality and customer-centric service philosophy, Qilu Pharmaceutical has established itself as a trusted brand in the pharmaceutical industry. The company's extensive sales network spans across major provinces and cities in China and extends to North America, the European Union, Japan, Australia, and other regions worldwide.Follow the official account below to see the world!
